ÃÀ¸ß÷
ÓªÒµ×Éѯ
Öйú£º
Email: marketing@medicilon.com.cn
ÓªÒµ×ÉѯרÏߣº400-780-8018
£¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©
´¨É³×ܲ¿µç»°: +86 (21) 5859-1500
ÍâÑó£º
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
Email:marketing@medicilon.com




1. 6ÔÂ19ÈÕ£¬£¬£¬£¬£¬£¬¾Ý¹ú¼ÒÒ©¼à¾Ö¹ÙÍø£¬£¬£¬£¬£¬£¬µÏÕÜÒ½Ò©¸ßÑ¡ÔñÐÔJAK1ÒÖÖÆ¼Á¸êÀûÎôÌæÄᣨÉÌÆ·ÃûΪ¸ßÈðÕÜ£©»ñÅú£¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁƸ´¾ÙÊÂÖÎÐÔÍâÖÜTϸ°ûÁܰÍÁö£¨r/r PTCL£©¡£¡£¡£¸ßÈðÕܳÉΪ¡°È«ÇòÊ׸öÇÒΨһ¡±Õë¶ÔPTCLµÄJAK1ÒÖÖÆ¼Á£¬£¬£¬£¬£¬£¬Ò²ÊÇÒÑÍùÊ®ÄêÀ´£¬£¬£¬£¬£¬£¬¸ÃÖÎÁÆÁìÓòÉÏÊеÄÊ׸öÁ¢ÒìÒ©¡£¡£¡£
2. 6ÔÂ20ÈÕ£¬£¬£¬£¬£¬£¬Ð»ªÖÆÒ©Ðû²¼Í¨¸æ³Æ£¬£¬£¬£¬£¬£¬¹«Ë¾²úÆ·ÆÕÈð°ÍÁÖ½ºÄÒ£¨150mg,75mg£©»ñÅúÉÏÊУ¬£¬£¬£¬£¬£¬ÓÃÓÚÖÎÁÆ´ø×´ðåÕîºóÉñ¾Í´¡¢ÏËά¼¡Í´¡£¡£¡£
3. 6ÔÂ20ÈÕ ÖйúÉúÎïÖÆÒ©×òÈÕÐû²¼£¬£¬£¬£¬£¬£¬1ÀàÁ¢ÒìÒ©èÛéÚËáÒÀ·î°¢¿Ë½º¡°Envonalkib (TQ-B3139)¡±»ñÅúÉÏÊУ¬£¬£¬£¬£¬£¬ÓÃÓÚδ¾Óɼä±äÐÔÁܰÍÁö¼¤Ã¸(ALK)ÒÖÖÆ¼ÁÖÎÁƵÄALKÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔ·ÇСϸ°û·Î°©(NSCLC)»¼ÕßµÄÖÎÁÆ¡£¡£¡£
4. 6ÔÂ19ÈÕ£¬£¬£¬£¬£¬£¬CDE¹ÙÍø¹«Ê¾£¬£¬£¬£¬£¬£¬¾¢·½Ò½Ò©ÉêÇëµÄ1ÀàÐÂÒ©GFH375Ƭ»ñÅúÁÙ´²£¬£¬£¬£¬£¬£¬Ä⿪·¢ÖÎÁÆKRAS G12DÍ»±äÑôÐÔµÄÍíÆÚʵÌåÁö»¼Õß¡£¡£¡£Æ¾Ö¤¾¢·½Ò½Ò©¹ûÈ»×ÊÁÏ£¬£¬£¬£¬£¬£¬GFH375ƬΪһ¿î¿Ú·þKRAS G12D£¨ON/OFF£©ÒÖÖÆ¼Á¡£¡£¡£
1. ¿ËÈÕ£¬£¬£¬£¬£¬£¬Ò¢ÌÆ£¨ÉϺ££©ÉúÎï¿Æ¼¼ÓÐÏÞ¹«Ë¾ÓëâýØûÉúÎï¿Æ¼¼£¨ÉϺ££©ÓÐÏÞ¹«Ë¾Ç©ÊðÁËÓµÓÐÒ¢ÌÆ×ÔÖ÷֪ʶ²úȨµÄȫлùÒò±à¼¹¤¾ßøYolCas12?µÄÉú²úÏúÊÛÔÊÐíÐÒé¡£¡£¡£Æ¾Ö¤ÐÒéÄÚÈÝ£¬£¬£¬£¬£¬£¬âýØûÉúÎォ»ñµÃÓÉÒ¢ÌÆ×ÔÖ÷Ñз¢µÄ YolCas12?ÔÚ´óÖлªÇøµÄÉú²úÏúÊÛÔÊÐí¡£¡£¡£
1. 6ÔÂ18ÈÕ£¬£¬£¬£¬£¬£¬ÖÐɽ´óѧÈËÀಡ¶¾Ñ§Ñо¿ËùËù³¤ÕÅ»ÔÍŶÓÔÚ Cell Reports Medicine ×îз¢ÎÄ¡£¡£¡£Ö÷Òª¿ª·¢ÁËÒ»ÖÖ»ùÓÚÌúÂѰ׵ÄÄÉÃ×Á£×ÓÒßÃ磬£¬£¬£¬£¬£¬¸ÃÒßÃçͨ¹ýÁ¬ÏµÈËÀàǰÂѰ×ת»¯Ã¸¿Ý²ÝÈܾúËØ 9£¨PCSK9£©×÷Ϊ¿¹Ô£¬£¬£¬£¬£¬£¬ÓÐÓÃÓÕµ¼±¬·¢×ÌÈÅ PCSK9 »îÐԵĿ¹Ì壬£¬£¬£¬£¬£¬´Ó¶ø½µµÍѪÇåÖ¬ÖÊˮƽ£¬£¬£¬£¬£¬£¬¶Ô¿¹¸ßµ¨¹Ì´¼ÑªÖ¢£¬£¬£¬£¬£¬£¬²¢ÔÚ¶¯ÎïÄ£×ÓÖÐÕ¹ÏÖ³öÓÅÒìµÄÇå¾²ÐԺͺã¾ÃÃâÒß³¤ÆÚÐÔ£¬£¬£¬£¬£¬£¬Îª¸ßµ¨¹Ì´¼ÑªÖ¢ºÍÐÄѪ¹Ü¼²²¡µÄÔ¤·ÀºÍÖÎÁÆÌṩÁËÒ»ÖÖеIJßÂÔ¡£¡£¡£
[1]Fang QN. et al. Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia. Cell Rep Med. 2024 June 18.
Ïà¹ØÐÂÎÅ